| answer text |
<p><del class="ministerial">We do not currently have a national mechanism to capture
and report incidents of violence and aggression in the National Health Service. Data
is held at a local level.</del></p><p> </p><p><del class="ministerial">At a national
level, data on self-reported violent incidents is gathered through the NHS Staff Survey.
Results from the 2022 NHS Staff Survey indicated that 14.7% of NHS staff have self-reported
that they have experienced at least one incident of physical violence from patients,
service users, relatives or other members of the public in the last 12 months.</del></p><p>
</p><p><del class="ministerial">27.8% of NHS staff who completed the NHS Staff Survey
experienced at least one incident of harassment, bullying or abuse in the last 12
months from patients or service users, their relatives or members of the public. This
figure is similar to previous years’ NHS Staff Survey data.</del></p><p> </p><p><del
class="ministerial">NHS England has commissioned a number of data insight workstreams
to better understand the current landscape of statistics, data reporting and associated
challenges. This includes a national review of all available data and intelligence
sources, an analysis of the costs of violence to the health care system in England
and a review of the impact on the safety and wellbeing of NHS staff.</del></p><p>
</p><p><del class="ministerial">The Ministry of Justice collects data on prosecution,
conviction and sentences for the offence of assault on an emergency worker, although
it does not identify the type of emergency worker. This data is available in the Criminal
Justice Statistics Quarterly and the Outcomes of Offence Tool and Offence Group Classification:
Criminal Justice System Statistics Quarterly: December 2022, a copy of which is attached.</del></p><p><ins
class="ministerial">The early access to medicines scheme (EAMS) aims to give patients
with life threatening or seriously debilitating conditions access to medicines that
do not yet have a marketing authorisation when there is a clear unmet medical need.</ins></p><p><ins
class="ministerial">Under the scheme, the Medicines and Healthcare products Regulatory
Agency (MHRA) will give a scientific opinion on the benefit/risk balance of the medicine,
based on the data available when the EAMS submission was made and the EAMS criteria.
The MHRA will make an evaluation of products, including drugs such as for brain tumour
treatments, once an application is received.</ins></p><p><ins class="ministerial">If
we do receive an application, it is only made public where an EAMS Scientific Opinion
(SO) is awarded. All EAMS SOs are published on the EAMS webpage. All drugs that have
previously held an EAMS SO are also published on the EAMS webpage.</ins></p>
|
|
